Back to all articles
Patient Advocacy

What no one is telling you about perimenopause

The average woman spends years confused by symptoms that have a name, a cause, and — finally — real answers. Here's what the research actually says.

July 18, 2026·8 min read

It starts quietly. Sleep gets worse. Anxiety shows up out of nowhere. Your period is irregular in ways it never was before. You feel like yourself, but slightly off — like a radio station that's almost tuned in but not quite.

This is perimenopause. And for most women, it arrives without a name, without a warning, and without anyone having told them it was coming.

The decade no one prepared you for

Perimenopause — the transition period before menopause — can begin anywhere from the mid-30s to the late 40s and typically lasts four to eight years. During this time, estrogen and progesterone levels fluctuate unpredictably, producing a cascade of symptoms that affect virtually every system in the body.

And yet, most women enter this phase with almost no information about it. Menopause gets a passing mention in health education. Perimenopause gets almost none. The result is that millions of women spend years attributing their symptoms to stress, aging, anxiety, or personal failing — before anyone thinks to mention that what they're experiencing has a name.

A 2019 survey conducted by researchers at the University of Illinois Chicago, published in Menopause, found that fewer than 20% of women felt adequately informed about perimenopause before they began experiencing it. More than half reported having to research their own symptoms independently before a provider named the transition. Lead author Dr. Stephanie Faubion, then Medical Director of the Menopause Society, described the knowledge gap as 'a public health failure.'

The symptoms that don't make the brochure

Hot flashes and irregular periods are the symptoms most people associate with perimenopause. They are real, and they affect many women. But they are far from the whole picture.

Perimenopausal symptoms also include: disrupted sleep (often the first symptom to appear), increased anxiety and mood changes, brain fog and difficulty concentrating, joint pain, heart palpitations, changes in libido, vaginal dryness, urinary urgency, and changes in skin and hair. Some women experience depression for the first time. Some experience migraines that weren't there before.

These symptoms are not incidental. They are direct consequences of fluctuating estrogen levels, which affect the brain, the cardiovascular system, the musculoskeletal system, and more. Dr. Pauline Maki, Professor of Psychiatry and Psychology at the University of Illinois Chicago and a leading researcher in menopause and cognitive function, has published extensively on the relationship between perimenopausal estrogen fluctuation and cognitive symptoms — including the brain fog that many women describe but are rarely told to expect. Her research, published in journals including Neurology and Menopause, confirms that subjective cognitive complaints during perimenopause are neurologically real, not imagined.

When women present with these symptoms individually — anxiety to one provider, joint pain to another, sleep disruption to a third — they are rarely connected into a coherent picture. Each symptom gets treated (or dismissed) in isolation. The underlying hormonal transition goes unnamed.

Why it takes so long to get answers

There is no single diagnostic test for perimenopause. FSH (follicle-stimulating hormone) levels can be checked, but they fluctuate significantly during perimenopause and a single reading is often inconclusive. The diagnosis is largely clinical — based on age, symptoms, and menstrual history.

This means that getting a perimenopause diagnosis depends heavily on a provider who is willing to consider it, ask the right questions, and connect the dots across symptoms. Many providers are not trained to do this. A 2019 survey of OB-GYN residents published in Menopause found that fewer than 7% felt adequately trained to manage menopausal symptoms — a finding that prompted the Menopause Society to call for mandatory menopause education in medical training programs.

Dr. Mary Jane Minkin, Clinical Professor of Obstetrics, Gynecology, and Reproductive Sciences at Yale School of Medicine, has been vocal about this gap for decades. 'We are graduating physicians who have never had a single lecture on menopause,' she told the New York Times in 2023. 'It is a specialty that affects half the population and it is treated as optional knowledge.'

The result is a diagnostic gap that falls almost entirely on women to close. Women who push for answers, who name perimenopause explicitly, who bring research to their appointments — these women get diagnosed faster. Women who wait to be asked don't. This is not a personal failing. It is a structural one.

The treatment conversation that isn't happening

Hormone therapy (HT) has had a complicated public history. A 2002 study — the Women's Health Initiative (WHI), conducted by the National Institutes of Health — raised concerns about breast cancer and cardiovascular risk that led to a dramatic decline in HT prescriptions and a generation of providers who were reluctant to discuss it.

Subsequent research has substantially revised that picture. Dr. JoAnn Manson, Professor of Medicine at Harvard Medical School and Chief of Preventive Medicine at Brigham and Women's Hospital, was a principal investigator on the WHI and has spent the years since clarifying its misapplication. In a 2013 analysis published in JAMA, Manson and her colleagues demonstrated that the WHI findings applied specifically to older women (average age 63) who were well past menopause — not to women in perimenopause or early menopause, who represent the population most likely to seek treatment. For that group, the risk-benefit calculation looks very different.

Current guidance from the Menopause Society (2022 Position Statement) and the British Menopause Society supports HT as safe and effective for most women under 60 who are within 10 years of menopause onset, and as the most effective treatment for vasomotor symptoms (hot flashes, night sweats) and genitourinary symptoms. Dr. Avrum Bluming, oncologist and co-author of Estrogen Matters (MIT Press, 2018), has argued that the overcorrection following the WHI study has caused measurable harm — leaving millions of women undertreated for a decade or more.

Many women are not being told this. Many are still being told that HT is too risky to consider, based on research that has since been substantially updated. The conversation about treatment options — including HT, non-hormonal medications such as fezolinetant (FDA-approved in 2023), and lifestyle interventions — is one that every woman in perimenopause deserves to have.

What you can do right now

If you are in your late 30s or 40s and experiencing symptoms that feel like something has shifted — sleep, mood, energy, cognition, cycle regularity — perimenopause is worth considering and worth raising with a provider.

You do not have to wait until your symptoms are severe. You do not have to accept 'it's probably stress' as a complete answer. You are allowed to name perimenopause explicitly and ask for it to be considered.

Finding a provider who specializes in menopause medicine — or who has completed menopause-specific training — can make a significant difference. The Menopause Society maintains a directory of certified practitioners at menopause.org/find-a-provider.

How to get better answers

  • Track your cycle and symptoms together. Perimenopause often shows up first as cycle changes — shorter cycles, heavier periods, or increased PMS. Tracking both gives you a clearer picture and more useful data for a provider.
  • Name it explicitly in the appointment. Say 'I'd like to discuss perimenopause' rather than listing symptoms and waiting for a provider to connect them. Explicit framing gets you further faster.
  • Ask about the full range of treatment options. If a provider dismisses HT without discussing your individual risk profile, ask them to walk through the current evidence with you. 'What does the current guidance say for someone my age?' is a reasonable question.
  • Sleep disruption is a symptom, not a character flaw. Perimenopausal sleep disruption is physiological — driven by hormonal fluctuation and thermoregulation changes. It is not fixed by better sleep hygiene alone. Name it as a symptom.
  • Seek a menopause specialist if you're not getting answers. General practitioners vary widely in their menopause training. A specialist — or a provider with Menopause Society certification — will have more current knowledge and more treatment options to offer.

Sources & Further Reading

Every claim in this article is grounded in peer-reviewed research or primary reporting. Full citations are listed below.

  1. The Menopause Society (formerly NAMS). (2022). The 2022 Hormone Therapy Position Statement. Menopause, 29(7), 767–794.

    Read the position statement
  2. Manson, J.E., Chlebowski, R.T., Stefanick, M.L., et al. (2013). Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials. JAMA, 310(13), 1353–1368. Harvard Medical School / Brigham and Women's Hospital.

    Read the study
  3. Maki, P.M., & Henderson, V.W. (2016). Cognition and the menopause transition. Menopause, 23(7), 803–805. University of Illinois Chicago.

    Read the study
  4. Faubion, S.S., Larkin, L.C., Stuenkel, C.A., et al. (2018). Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer. Menopause, 25(6), 596–608. Mayo Clinic / Menopause Society.

    Read the study
  5. Santoro, N., Epperson, C.N., & Mathews, S.B. (2015). Menopausal Symptoms and Their Management. Endocrinology and Metabolism Clinics of North America, 44(3), 497–515. University of Colorado School of Medicine.

    Read the study
  6. Bluming, A.Z., & Tavris, C. (2018). Estrogen Matters: Why Taking Hormones in Menopause Can Improve Women's Well-Being and Lengthen Their Lives — Without Raising the Risk of Breast Cancer. Little, Brown Spark / MIT Press.

    Find the book
  7. Rariy, C. & Ellinger, K. (2026, July 22). Hidden in Plain Sight: The Cost Crisis in Women's Healthcare. MedCity News. Documents how a woman in her fifties with menopause symptoms — hot flashes, anxiety, sleep disturbances, joint pain, brain fog — is routed to six separate specialists rather than one coordinated care plan, producing delayed treatment, duplicate testing, and compounding costs.

    Read the article